Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Practice Guidelines
    • Featured Practice Guidelines
    • Migraine Headache...

    Migraine Headache Guidelines: US Headache Consortium, American Headache Society

    Written by Vinay Singh singh Published On 2019-02-15T19:00:20+05:30  |  Updated On 15 Feb 2019 7:00 PM IST
    Migraine Headache Guidelines: US Headache Consortium, American Headache Society

    The American Academy of Neurology and the American Headache Society collaboratively released guidelines on the pharmacologic treatment for episodic migraine prevention in adults.


    Migraine is a common, disabling, and costly disorder. There is no cure, but preventive treatment to decrease the number and severity of headache attacks improves health outcomes and quality of life.3 It also reduces disability and costs.


    The initial selection of agents should be based on the level of established efficacy. Routinely evaluate patient response and utilize factors such as comorbidities, personal considerations, and adverse reactions to guide and individualize therapy. Comparisons of efficacy amongst agents of the same drug class for short-term as well as chronic use have not been established by the evidence currently available.


    Read Also: Women suffering from migraine have lower diabetes risk : JAMA


    Frequent or high dosing of these medications can lead to rebound headaches and progression to chronic headache disorders. Initiate at the lowest possible dose then increase to desired effect or development of an adverse reaction. An adequate trial length is between 2−6months. Discontinuation via a taper is encouraged if a patient is well-controlled after 6−12months of therapy.


    According to the guidelines, the following medications are established as effective and should be offered for migraine prevention (level A recommendation):




    • Antiepileptic drugs (AEDs): divalproex sodium, sodium valproate, topiramate

    • β-Blockers: metoprolol, propranolol, timolol

    • Triptans: frovatriptan for short-term MAMs prevention


    The following medications are probably effective and should be considered for migraine prevention (level B recommendation):




    • Antidepressants: amitriptyline, venlafaxine

    • β-Blockers: atenolol, nadolol

    • Triptans: naratriptan, zolmitriptan for short-term MAMs prevention


    The following medications are possibly effective and may be considered for migraine prevention (level C recommendation):




    • ACE inhibitors: lisinopril

    • Angiotensin receptor blockers: candesartan

    • α-Agonists: clonidine, guanfacine

    • AEDs: carbamazepine

    • β-Blockers: nebivolol, pindolol


    NSAIDs and other complementary treatments for episodic migraine prevention in adults


    The American Academy of Neurology and the American Headache Society also released guidelines regarding the use of NSAIDs and complementary treatments in preventing episodic migraine.


    Read Also: Migraine with visual aura increases risk for irregular heartbeat


    The following therapy is established as effective and should be offered for migraine prevention (level A recommendation):




    • Petasites (butterbur)


    The following therapies are probably effective and should be considered for migraine prevention (level B recommendation):




    • NSAIDS: fenoprofen, ibuprofen, ketoprofen, naproxen, naproxen sodium

    • Herbal therapies, vitamins, and minerals: riboflavin, magnesium, MIG-99 (feverfew)

    • Histamines: histamine SC


    The following therapies are possibly effective and may be considered for migraine prevention (level C recommendation):




    • NSAIDs: flurbiprofen, mefenamic acid

    • Herbal therapies, vitamins, and minerals: Co-Q10, estrogen

    • Antihistamines: cyproheptadine

    drugsepisodicguidelinesmanagementMedicinemigrainepharmacologicalPosition Statementpreventionprophylaxisrecommendationstreatment

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Vinay Singh singh
    Vinay Singh singh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok